Zometa Study in Pediatric Acute Lymphoblastic Leukemia
Status:
Completed
Trial end date:
2015-08-01
Target enrollment:
Participant gender:
Summary
Acute Lymphoblastic Leukemia (ALL) is the most common malignancy in children. It accounts for
one fourth of all childhood cancers & 74 % of childhood leukemia. Based upon drug registry
data, children prescribed more than three courses of systemic glucocorticoids yearly faced a
20% increase in age-adjusted fracture rates. Rapid recovery occurred once glucocorticoids
were discontinued, and fracture rates returned to expected for age by 1 year after treatment
(Journal Of Clinical Endocrinology & Metabolism 2009). The investigators will study the role
of bisphosphonates in the prevention of secondary osteoporosis in children & adolescents
treated for ALL in the Children's Cancer Hospital -Egypt.
Phase:
Phase 3
Details
Lead Sponsor:
Children's Cancer Hospital Egypt 57357
Treatments:
Calcium Calcium, Dietary Diphosphonates Ergocalciferols Vitamin D Vitamins